Search

Kejian C Zhang

from Stamford, CT
Age ~54
Get Report
Also known as:
Zhang Kejian, Keijan Zhang, Jian Zhang Ke
Related to:
Shan Zheng, 61Zhilan Zhang, 60Jing Wang, 52Kejian Wang, 54Zhaohui Wang, 55Xiaoxin Wang, 59Xiufang Zhang, 78
Connected to:
Aimei Zhang, 44Aining Zhang, 30Aiqing Zhang, 50Alexia Y Zhang, 36Amy X Zhang, 57Angelina Zhang, 54Ashley C Zhang, 60Baomin Zhang, 55Beilei Zhang, 45Carl Zhang, 33

Kejian Zhang Phones & Addresses

  • Stamford, CT
  • 7616 Holliston Pl, Cincinnati, OH 45255 (513) 961-0739
  • Blue Ash, OH
  • 7616 Holliston Pl, Cincinnati, OH 45255

Resumes

Resumes

Kejian Zhang Photo 1

Medical Genetist

View page
Location:
Cincinnati, OH
Industry:
Hospital & Health Care
Work:
Cincinnati Childrens Hospital Medical Center
Medical Genetist
Education:
University of Cincinnati Carl H. Lindner College of Business 1999 - 2001
Master of Business Administration, Masters, International Business, Finance
Skills:
Clinical Research
Healthcare
Hospitals
Pediatrics
Kejian Zhang Photo 2

Kejian Zhang

View page

Publications

Us Patents

Diagnostic Assay For Wiskott-Aldrich Syndrome And Genetically Related Disorders

View page
US Patent:
20060134673, Jun 22, 2006
Filed:
Dec 6, 2005
Appl. No.:
11/295149
Inventors:
Kejian Zhang - Cincinnati OH, US
Richard Wenstrup - Cincinnati OH, US
Alexandra Filipovich - Covington KY, US
International Classification:
C12Q 1/68
C12P 19/34
C07H 21/04
US Classification:
435006000, 435091200, 536023100
Abstract:
The methods and compositions of the invention find use in the clinical diagnosis of primary immunodeficiencies, particularly Wiskott-Aldrich related syndromes. The compositions of the invention include isolated nucleic acid molecules and oligonucleotide pairs suitable for use in amplifying regions of the Wiskott-Aldrich syndrome protein gene and in determining the nucleotide sequence of the Wiskott-Aldrich syndrome protein gene in a patient. The invention facilitates efficient, cost-effective amplification of one or more regions of the Wiskott-Aldrich syndrome protein gene. The nucleotide sequence of amplified DNA comprising one or more regions of the Wiskott-Aldrich Syndrome Protein gene can be determined using the methods and compositions of the invention. Knowledge of the patient's nucleotide sequence in the Wiskott-Aldrich Syndrome Protein gene allows diagnosis of the patient's primary immunodeficiency.

Diagnostic Assay For Autoimmune Lymphoproliferative Syndrome (Alps) And Genetically Related Disorders

View page
US Patent:
20080090234, Apr 17, 2008
Filed:
Oct 13, 2006
Appl. No.:
11/580529
Inventors:
Kejian Zhang - Cincinnati OH, US
Richard J. Wenstrup - Cincinnati OH, US
Jacob J. Bleesing - Cincinnati OH, US
Alexandra H. Filipovich - Covington KY, US
International Classification:
C12Q 1/68
C07H 21/04
C12P 19/34
US Classification:
435 6, 435 912, 536 231
Abstract:
The methods and compositions of the invention find use in the clinical diagnosis of TNFRSF6-related syndromes, particularly autoimmune lymphoproliferative syndrome (ALPS). The compositions of the invention include isolated nucleic acid molecules and oligonucleotide pairs suitable for use in amplifying regions of the TNFRSF6 gene and in determining the nucleotide sequence of the TNFRSF6 gene in a patient. The invention facilitates efficient, cost-effective amplification of one or more regions of the TNFRSF6 gene. The nucleotide sequence of amplified DNA comprising one or more regions of the TNFRSF6 gene can be determined. Knowledge of the patient's nucleotide sequence in the TNFRSF6 gene allows diagnosis of the patient.

Personalized Pain Management And Anesthesia: Preemptive Risk Identification And Therapeutic Decision Support

View page
US Patent:
20200340061, Oct 29, 2020
Filed:
Jun 19, 2020
Appl. No.:
16/946401
Inventors:
- Cincinnati OH, US
Vidya Chidambaran - Cincinnati OH, US
John McAuliffe - Cincinnati OH, US
Kejian Zhang - Cincinnati OH, US
Jaroslaw Meller - Cincinnati OH, US
Cynthia A. Prows - Cincinnati OH, US
Tsuyoshi Fukuda - Cincinnati OH, US
International Classification:
C12Q 1/6883
Abstract:
Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids. Therefore, patients who are genetically predisposed to risk of inadequate pain relief and/or serious side effects from anesthesia, analgesics, and/or opioids can be identified and individualized treatment plans developed for implementation by the clinician to improve clinical and economic outcomes.

Personalized Pain Management And Anesthesia: Preemptive Risk Identification And Therapeutic Decision Support

View page
US Patent:
20200318194, Oct 8, 2020
Filed:
Jun 19, 2020
Appl. No.:
16/946399
Inventors:
- Cincinnati OH, US
Vidya Chidambaran - Cincinnati OH, US
John McAuliffe - Cincinnati OH, US
Kejian Zhang - Cincinnati OH, US
Jaroslaw Meller - Cincinnati OH, US
Cynthia A. Prows - Cincinnati OH, US
Tsuyoshi Fukuda - Cincinnati OH, US
International Classification:
C12Q 1/6883
Abstract:
Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids. Therefore, patients who are genetically predisposed to risk of inadequate pain relief and/or serious side effects from anesthesia, analgesics, and/or opioids can be identified and individualized treatment plans developed for implementation by the clinician to improve clinical and economic outcomes.

Personalized Pain Management And Anesthesia: Preemptive Risk Identification And Therapeutic Decision Support

View page
US Patent:
20200308648, Oct 1, 2020
Filed:
Apr 16, 2020
Appl. No.:
16/850537
Inventors:
- Cincinnati OH, US
Vidya Chidambaran - Cincinnati OH, US
John McAuliffe - Cincinnati OH, US
Kejian Zhang - Cincinnati OH, US
Jaroslaw Meller - Cincinnati OH, US
Cynthia A. Prows - Cincinnati OH, US
Tsuyoshi Fukuda - Cincinnati OH, US
International Classification:
C12Q 1/6883
Abstract:
Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids. Therefore, patients who are genetically predisposed to risk of inadequate pain relief and/or serious side effects from anesthesia, analgesics, and/or opioids can be identified and individualized treatment plans developed for implementation by the clinician to improve clinical and economic outcomes.

Personalized Pain Management And Anesthesia: Preemptive Risk Identification And Therapeutic Decision Support

View page
US Patent:
20180334717, Nov 22, 2018
Filed:
Aug 9, 2018
Appl. No.:
15/915581
Inventors:
- Cincinnati OH, US
Vidya Chidambaran - Cincinnati OH, US
John McAuliffe - Cincinnati OH, US
Kejian Zhang - Cincinnati OH, US
Jarolsaw Meller - Cincinnati OH, US
Cynthia A. Prows - Cincinnati OH, US
Tsuyoshi Fukuda - Cincinnati OH, US
International Classification:
C12Q 1/6883
Abstract:
Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids. Therefore, patients who are genetically predisposed to risk of inadequate pain relief and/or serious side effects from anesthesia, analgesics, and/or opioids can be identified and individualized treatment plans developed for implementation by the clinician to improve clinical and economic outcomes.

Compositions And Methods For Screening For Creatine Transporter Deficiency

View page
US Patent:
20140377757, Dec 25, 2014
Filed:
May 25, 2012
Appl. No.:
14/122274
Inventors:
- Cincinnati OH, US
Yuko Kurosawa - Kusatsu, JP
Kejian Zhang - Cincinnati OH, US
Wenying Zhang - Blue Ash OH, US
Mehdi Keddache - Ludlow KY, US
Assignee:
UNIVERSITY OF CINCINNATI - CINCINNATI OH
International Classification:
C12Q 1/68
US Classification:
435 612
Abstract:
Amplification primers, sequencing primers, kits for screening, and screening methods for identifying a SLC6A8 creatine transporter gene mutation are disclosed. The screening method includes treating a sample of DNA with polymerase chain reaction amplification primers for amplifying regions of the DNA having SLC6A8 to produce a first, second, and third amplification product, sequencing the first, second, and third amplification products with sequencing primer pairs to provide a DNA sequence of SLC6A8 in the sample, and comparing the DNA sequence of SLC6A8 with a reference DNA sequence of SLC6A8.

Personalized Pain Management And Anesthesia: Preemptive Risk Identification And Therapeutic Decision Support

View page
US Patent:
20140371256, Dec 18, 2014
Filed:
Nov 29, 2012
Appl. No.:
14/361946
Inventors:
- Cincinnati OH, US
John McAuliffe - Cincinnati OH, US
Kejian Zhang - Cincinnati OH, US
Jarolsaw Meller - Cincinnati OH, US
Cynthia A. Prows - Cincinnati OH, US
Tsuyoshi Fukuda - Cincinnati OH, US
International Classification:
C12Q 1/68
US Classification:
514282, 435 611, 506 9, 506 2
Abstract:
Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids. Therefore, patients who are genetically predisposed to risk of inadequate pain relief and/or serious side effects from anesthesia, analgesics, and/or opioids can be identified and individualized treatment plans developed for implementation by the clinician to improve clinical and economic outcomes.
Control profile
Kejian C Zhang from Stamford, CT, age ~54 Get Report